Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI

Pharm Dev Technol. 2020 Jun;25(5):566-578. doi: 10.1080/10837450.2020.1720235. Epub 2020 Feb 6.

Abstract

The current work aimed to develop low-density gastroretentive sponges loaded with alfuzosin HCl (ALF) to sustain the rate of drug release, improve its oral bioavailability and deliver it to the main site of absorption. Sponges were developed, according to a 23 full factorial design, by compression of the lyophilized ALF-loaded hydroxypropylmethylcellulose (HPMC) or chitosan (CH) solutions. The influences of the polymer type, grade and concentration on the appearance, topography, porosity, density, in vitro ALF release, floating behavior, swelling, erosion, and mucoadhesive potential of the developed sponges were explored. Based on the desirability value, the best achieved system was selected. The gastroretentive potential of this system was evaluated in healthy male volunteers via MRI. Soft and flexible sponges were developed. They were characterized with interconnecting pores and channels and had excellent floating properties with respect to floating lag time and duration. Compared to HPMC-based sponges, CH-based ones exhibited higher porosity, larger pore diameters, lower bulk densities, higher drug release rates, larger swelling ratios, faster erosion rates and better mucoadhesive properties. MRI of magnetite-loaded best-achieved CH-based system (F8) ascertained the development of a promising gastroretentive system; exhibiting a gastric residence period of at least 5 h.

Keywords: Alfuzosin hydrochloride; gastroretentive potential; low-density; magnetic resonance imaging; magnetite-loaded sponges.

MeSH terms

  • Abdomen / diagnostic imaging
  • Adrenergic alpha-1 Receptor Antagonists / administration & dosage
  • Adrenergic alpha-1 Receptor Antagonists / chemistry*
  • Adrenergic alpha-1 Receptor Antagonists / pharmacokinetics
  • Biological Availability
  • Chitosan / chemistry
  • Drug Carriers / chemistry
  • Drug Compounding / methods*
  • Drug Delivery Systems / methods*
  • Drug Liberation
  • Drug Monitoring / instrumentation
  • Drug Monitoring / methods*
  • Ferrosoferric Oxide / chemistry
  • Gastric Mucosa / metabolism
  • Healthy Volunteers
  • Humans
  • Hypromellose Derivatives / chemistry
  • Magnetic Resonance Imaging*
  • Porosity
  • Quinazolines / administration & dosage
  • Quinazolines / chemistry*
  • Quinazolines / pharmacokinetics
  • Solubility
  • Surface Properties

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Drug Carriers
  • Quinazolines
  • Hypromellose Derivatives
  • Chitosan
  • alfuzosin
  • Ferrosoferric Oxide